1. Home
  2. TBPH vs MEI Comparison

TBPH vs MEI Comparison

Compare TBPH & MEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • MEI
  • Stock Information
  • Founded
  • TBPH 2013
  • MEI 1946
  • Country
  • TBPH United States
  • MEI United States
  • Employees
  • TBPH N/A
  • MEI N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • MEI Electrical Products
  • Sector
  • TBPH Health Care
  • MEI Technology
  • Exchange
  • TBPH Nasdaq
  • MEI Nasdaq
  • Market Cap
  • TBPH 464.5M
  • MEI 464.2M
  • IPO Year
  • TBPH N/A
  • MEI N/A
  • Fundamental
  • Price
  • TBPH $9.01
  • MEI $6.54
  • Analyst Decision
  • TBPH Buy
  • MEI Buy
  • Analyst Count
  • TBPH 4
  • MEI 3
  • Target Price
  • TBPH $13.75
  • MEI $11.67
  • AVG Volume (30 Days)
  • TBPH 192.5K
  • MEI 621.2K
  • Earning Date
  • TBPH 05-12-2025
  • MEI 03-05-2025
  • Dividend Yield
  • TBPH N/A
  • MEI 8.59%
  • EPS Growth
  • TBPH N/A
  • MEI N/A
  • EPS
  • TBPH N/A
  • MEI N/A
  • Revenue
  • TBPH $64,381,000.00
  • MEI $1,068,300,000.00
  • Revenue This Year
  • TBPH $51.09
  • MEI N/A
  • Revenue Next Year
  • TBPH N/A
  • MEI $5.40
  • P/E Ratio
  • TBPH N/A
  • MEI N/A
  • Revenue Growth
  • TBPH 12.12
  • MEI N/A
  • 52 Week Low
  • TBPH $7.44
  • MEI $5.84
  • 52 Week High
  • TBPH $10.90
  • MEI $17.45
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 41.82
  • MEI 33.93
  • Support Level
  • TBPH $8.72
  • MEI $6.21
  • Resistance Level
  • TBPH $9.55
  • MEI $7.02
  • Average True Range (ATR)
  • TBPH 0.25
  • MEI 0.31
  • MACD
  • TBPH -0.04
  • MEI 0.13
  • Stochastic Oscillator
  • TBPH 34.94
  • MEI 40.12

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About MEI Methode Electronics Inc.

Methode Electronics Inc makes component and subsystem devices employing electrical, radio remote control, electronic, wireless, and sensing technologies. The firm is organized into various business segments: Automotive, Industrial, Interface, and Medical. The Automotive segment which generates maximum revenue, supplies electronic and electro-mechanical devices and related products to automobiles. The products manufactured in the automotive segment include overhead and center consoles, hidden and ergonomic switches, insert molded components, LED-based lighting, and sensors. Geographically, the company generates maximum revenue from North America and the rest from Europe, the Middle East & Africa (EMEA), and Asia.

Share on Social Networks: